Skip to main content
Clinical Trials/NL-OMON46145
NL-OMON46145
Completed
Not Applicable

HEMOdynamic guidance with PA-sensor CardioMEMS in patients with an left ventricular assist device (LVAD) - HEMO-VAD pilot

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
10
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • \-Signed Informed Consent Form (ICF)
  • \-Age \*18 years
  • \-LVEF \<25%
  • \-NYHA Class III with dyspnea upon mild physical activity or NYHA Class IV with INTERMACS classes 2\-5
  • \-Scheduled or intended for LVAD implantation within 1 month
  • \-Body surface Area \>\<\= 1\.2 m2 and chest circumference, at the axillary level, of less than 65 inches if BMI \>35 kg/m2

Exclusion Criteria

  • \*No written informed consent
  • \*Patients with contra\-indications for the PA pressure sensor device, which will include active infection, a history of deep vein thrombosis or recurrent pulmonary embolism,
  • \*Patients unable to tolerate right heart catheterization
  • \*Intolerance to anticoagulant or antiplatelet therapies
  • \*Patients with a known coagulation disorder or hypersensitivity to aspirin.
  • \*History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (\>1 episode) pulmonary embolism and/or deep vein thrombosis
  • \*Fixed pulmonary hypertension with a most recent PVR \* 8 Wood units that is unresponsive to pharmacologic intervention (which makes CardioMEMS sensor no additive value)
  • \*History of stroke within 90 days prior to enrollment, or a history of cerebrovascular disease with significant (\> 80%) uncorrected carotid stenosis
  • \*Serum creatinine \* 221 umol/L or eGFR below 25 or the need for chronic renal replacement therapy
  • \*Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAD management

Outcomes

Primary Outcomes

Not specified

Similar Trials